Tango Therapeutics (TNGX) R&D chief reports RSU grant, option and tax sales

Rhea-AI Filing Summary

Tango Therapeutics President of R&D Crystal Adam reported new equity awards and related tax sales of common stock. On February 2, 2026, she received 47,460 restricted stock units, each equal to one share, vesting 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to continued service. She also received a stock option for 284,760 shares at an exercise price of $11.94, vesting 25% on January 1, 2027 and monthly thereafter for three years. To cover tax withholding from RSU vesting under the company’s sell-to-cover policy, she automatically sold 18,251 shares at a weighted average $12.2573 and 201 shares at a weighted average $12.8971 on February 3, 2026. After these transactions, she directly owned 187,218 common shares and 284,760 options.

Insider Trade Summary

Net Seller: 18,452 shares ($226,300)

Net Sell 4 txns

Insider Crystal Adam

Role President, R&D

Sold 18,452 shs ($226K)

Type	Security	Shares	Price	Value
Sale	Common Stock	18,251	$12.2573	$224K
Sale	Common Stock	201	$12.8971	$3K
Grant/Award	Stock Option (Right to Buy)	284,760	$0.00	--
Grant/Award	Common Stock	47,460	$0.00	--

Holdings After Transaction: Common Stock — 187,419 shares (Direct); Stock Option (Right to Buy) — 284,760 shares (Direct)

Footnotes (1)

1. These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Represents the weighted average sales price per share. The shares sold at prices ranging from $11.88 to $12.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. The shares sold at prices ranging from $12.88 to $12.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2027 with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crystal Adam

(Last) (First) (Middle)

C/O TANGO THERAPEUTICS, INC.,

201 BROOKLINE AVE., SUITE 901

(Street)

BOSTON MA 02215

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		A		47,460(1)	A	$0	205,670	D
Common Stock	02/03/2026		S(2)		18,251	D	$12.2573(3)	187,419	D
Common Stock	02/03/2026		S(2)		201	D	$12.8971(4)	187,218	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.94	02/02/2026		A		284,760		(5)	02/02/2036	Common Stock	284,760	$0	284,760	D

Explanation of Responses:

1. These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

2. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

3. Represents the weighted average sales price per share. The shares sold at prices ranging from $11.88 to $12.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

4. Represents the weighted average sales price per share. The shares sold at prices ranging from $12.88 to $12.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

5. This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2027 with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

	/s/ Daniella Beckman, as attorney-in-fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Tango Therapeutics (TNGX) insider Crystal Adam report on this Form 4?

Crystal Adam reported new equity compensation and related tax sales. She received 47,460 restricted stock units and a stock option for 284,760 shares, plus automatic sell-to-cover stock sales tied to RSU vesting, all dated in early February 2026.

How many Tango Therapeutics (TNGX) RSUs were granted to Crystal Adam and how do they vest?

She was granted 47,460 restricted stock units, each equal to one share. The RSUs vest over three years: 33% on February 1, 2027, 33% on February 14, 2028, and 34% on February 12, 2029, assuming continued service with the company.

What stock option did Crystal Adam receive from Tango Therapeutics (TNGX)?

She received a stock option covering 284,760 shares of common stock at an exercise price of $11.94 per share. The option vests 25% on January 1, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, subject to continued service.

Why did Crystal Adam sell Tango Therapeutics (TNGX) shares on February 3, 2026?

The sales were made under Tango Therapeutics’ sell-to-cover policy to satisfy tax withholding from RSU vesting. The filing states these sales were automatic, not discretionary, and only covered the number of shares needed for withholding obligations.

At what prices were Crystal Adam’s Tango Therapeutics (TNGX) shares sold?

18,251 shares were sold at a weighted average price of $12.2573 per share, with trades between $11.88 and $12.875. Another 201 shares were sold at a weighted average of $12.8971, with prices between $12.88 and $12.91, according to the filing.

How many Tango Therapeutics (TNGX) shares and options does Crystal Adam hold after these transactions?

After the reported transactions, she directly held 187,218 shares of Tango Therapeutics common stock and 284,760 stock options. These figures reflect the post-transaction balances disclosed in the Form 4 tables for non-derivative and derivative securities.